Novartis (VTX:NOVN) Given a CHF 102 Price Target at Goldman Sachs Group
Goldman Sachs Group set a CHF 102 price objective on Novartis (VTX:NOVN) in a report released on Thursday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.
Several other equities analysts have also recently issued reports on NOVN. Jefferies Financial Group set a CHF 105 price objective on Novartis and gave the company a buy rating in a report on Wednesday, March 27th. JPMorgan Chase & Co. set a CHF 85 price objective on Novartis and gave the company a sell rating in a report on Wednesday, April 3rd. Deutsche Bank set a CHF 85 price objective on Novartis and gave the company a neutral rating in a report on Friday, April 5th. Credit Suisse Group set a CHF 84 price objective on Novartis and gave the company a neutral rating in a report on Friday, April 5th. Finally, Barclays set a CHF 75 price objective on Novartis and gave the company a sell rating in a report on Monday, April 8th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the stock. Novartis currently has a consensus rating of Hold and an average price target of CHF 89.18.
Novartis has a fifty-two week low of CHF 72.45 and a fifty-two week high of CHF 88.30.
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
Recommended Story: What is the NASDAQ?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.